Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway

Table 2 Pre- and post-diagnosis low-dose aspirin use and cause-specific survival following an ovarian cancer diagnosis: epithelial ovarian cancers diagnosed in Norway 2004–2018

Timing of exposure and exposure level	Deaths	Person-years	HR^a		95% CI
Pre-diagnosis
No aspirin	1774	15,088	Ref.
Aspirin use	199	1210	1.08	0.92	-	1.26
Post-diagnosis, Baseline exposure
No aspirin	1843	15,431	Ref.
Aspirin use	130	867	1.02	0.84	-	1.24
Only post	49	341	0.97	0.72	-	1.30
Pre and post	81	526	1.06	0.84	-	1.33
Post-diagnosis, Updated exposure
No aspirin	1789	14,336	Ref.
Ever aspirin	184	1968	0.76	0.64	-	0.89
Current aspirin	141	1663	0.68	0.57	-	0.81
Past aspirin	43	305	1.25	0.91	-	1.70
No aspirin	1789	14,336	Ref.
DDD < median	132	944	0.85	0.71	-	1.03
DDD ≥ median	52	1024	0.57	0.42	-	0.76

^aMultivariable models controlling for age at diagnosis (continuous), histology groups (high grade serous, low grade serous, endometrioid, mucinous, clear cell, carcinosarcoma), stage (localized, regional, distant, missing), ethnicity (Norway, other Nordic, other), education (mandatory level, secondary, higher education, missing), marital status (single, married/partnered, widowed/separated/divorced), and use of other medications at baseline (medications indicated for cardiovascular disease, and statins and anti-diabetics) Abbreviations: DDD = Defined Daily Dose; NSAIDs = non-steroidal anti-inflammatory drugs; NA-NSAIDs = non-aspirin NSAIDs

ISSN: 1471-2407